anti-PSMA/anti-CD70 4SCAR-expressing bispecific T cells

A preparation of T lymphocytes that are genetically engineered to express a fourth-generation chimeric antigen receptor (4SCAR) targeting the two tumor-associated antigens (TAAs) prostate-specific membrane antigen (PSMA) and CD70 (CD27 ligand; tumor necrosis factor superfamily member 7; TNFSF7), with potential immunostimulating and antineoplastic activities. Upon administration, the anti-PSMA/anti-CD70 4SCAR-expressing bispecific T cells are directed to and induce selective toxicity in PSMA- and CD70-expressing tumor cells. PSMA, a type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells as well as a variety of other solid tumors, including brain tumor, neuroblastoma and some lymphoma tumor tissues. CD70, a cytokine belonging to the tumor necrosis superfamily (TNFSF) and the ligand for the costimulatory receptor CD27, is expressed on the surfaces of various types of cancer cells; its overexpression may play an important role in the evasion of immune surveillance.